Product Information
Products Name
:
Semaglutide
CAS No.
: 910463-68-2
Purity
: >99.0%
Molecular Formula
: C187H291N45O59
Molecular Weight
: 4113.64g/mol
Sequence
:
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18diacid-γ-Glu-OEG-OEG)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Appearance
: White Lyophilized powder
Reconstitution
: Required
Storage
:After reconstitution store at 2°C - 8°C
Description:
What is Semaglutide
?
Semaglutide
is the newest GLP-1R
agonist and was approved by the FDA as a once-weekly injection for the treatment of T2DM in late 2023. The peptide is chemically similar to liraglutide, with the inclusion of two structural modifications (
Lau, Bloch, et al., 2015
). The first is the replacement of Gly with the non-proteinogenic amino acid 2-aminoisobutyric acid (Aib) at position 2. The second is the attachment of octadecanoic diacid to the side chain of Lys-26 through a short polyethylene glycol (PEG) spacer and a γ-glutamic acid linker. The amino acid substitution renders the peptide more resistant to DPP-4 compared to liraglutide, and the presence of the 18-carbon fatty acid moiety results in a high binding affinity for serum albumin, which translates to a half-life of approximately 7 days in humans